Prospective new biological therapies for rheumatoid arthritis
- 31 December 2009
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 9 (2), 102-107
- https://doi.org/10.1016/j.autrev.2009.03.010
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Co-stimulatory modulation in rheumatoid arthritis: The role of (CTLA4-Ig) abataceptAutoimmunity Reviews, 2008
- Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging studyArthritis & Rheumatism, 2008
- Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based TherapiesThe Cancer Journal, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritisArthritis & Rheumatism, 2008
- Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis modelRheumatology, 2007
- Epigenetics in inflammatory rheumatic diseasesArthritis & Rheumatism, 2007
- Selective therapeutic control of C5a and the terminal complement complex by anti‐C5 single‐chain Fv in an experimental model of antigen‐induced arthritis in ratsArthritis & Rheumatism, 2007
- IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in ratsArthritis Research & Therapy, 2007
- Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction?Annals Of The Rheumatic Diseases, 1993